Suppr超能文献

多种转录因子的共表达与生长激素分泌型垂体腺瘤的临床特征及内分泌预后相关。

Co-expression of multiple transcription factors is associated with clinical features and endocrine prognosis in growth hormone-secreting pituitary adenomas.

作者信息

Zhang Yu, Tang Hanlu, Li Shiwei, Bie Zhixu, Ma Xin, Wu Hongyu, Liu Gemingtian, Wang Xingchao, Liu Pinan, Yang Zhijun

机构信息

Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China.

Department of Neural Reconstruction, Beijing Key Laboratory of Central Nervous System Injury, Beijing Neurosurgical Institute, Capital Medical University, Beijing, PR China.

出版信息

Endocrine. 2025 Feb;87(2):788-799. doi: 10.1007/s12020-024-04082-x. Epub 2024 Oct 25.

Abstract

BACKGROUND

The types of growth hormone-secreting pituitary adenomas are diverse, we have found that there are significant differences in clinical features and prognosis between PIT-1 single-cell spectrum growth hormone adenomas and growth hormone phenotypic polyhormonal adenomas.

METHODS

This study examined a cohort of 193 patients with growth hormone-secreting pituitary adenoma (GHPA), stratifying them into two groups: PIT-1 single transcription factor positive growth hormone adenoma (STF-GHPA) and Multiple transcription factor-positive growth hormone-secreting adenomas (MTF-GHPA). The objective was to compare these two groups' clinical characteristics. Within the MTF-GHPA group, we further subtyped them based on transcription factors to evaluate potential variations in clinical manifestations. Logistic regression analyses were employed to develop a risk factor model for investigating factors influencing hormone remission.

RESULTS

There were no statistically significant differences in terms of age, gender, serum GH, and IGF-1 levels between patients diagnosed with MTF-GHPA and STF-GHPA. However, patients with MTF-GHPA exhibited a higher proportion of hypopituitarism compared to those with STF-GHPA. Furthermore, MTF-GHPA were characterized by smaller tumor size and less invasiveness, as indicated by lower Knosp classes. However, patients with MTF-GHPA have a lower rate of hormonal remission (30.8%) and more postoperative complications (31.0%), which means that STF-GHPA (hormonal remission:71.6%; postoperative complications:13.4%) has a better endocrine outcome than MTF-GHPA patients. Between the PIT-1 + SF-1+ and PIT-1 + TPIT+ subtypes within MTF-GHPA, significant differences were also observed in tumor size, endocrine outcomes, and postoperative complications. Risk factors influencing hormonal remission for GHPA included preoperative GH level, primary/recurrent, extent of resection, and transcription factor expression.

CONCLUSION

Co-expression of multiple transcription factors is an important factor associated with clinical behavior and endocrine outcomes in patients with GHPA.

摘要

背景

分泌生长激素的垂体腺瘤类型多样,我们发现PIT-1单细胞谱系生长激素腺瘤与生长激素表型多激素腺瘤在临床特征和预后方面存在显著差异。

方法

本研究对193例分泌生长激素的垂体腺瘤(GHPA)患者进行了研究,将他们分为两组:PIT-1单转录因子阳性生长激素腺瘤(STF-GHPA)和多转录因子阳性生长激素分泌腺瘤(MTF-GHPA)。目的是比较这两组的临床特征。在MTF-GHPA组中,我们根据转录因子进一步对其进行亚型分类,以评估临床表现的潜在差异。采用逻辑回归分析建立风险因素模型,以研究影响激素缓解的因素。

结果

诊断为MTF-GHPA和STF-GHPA的患者在年龄、性别、血清GH和IGF-1水平方面无统计学显著差异。然而,与STF-GHPA患者相比,MTF-GHPA患者垂体功能减退的比例更高。此外,MTF-GHPA的特点是肿瘤体积较小,侵袭性较小,Knosp分级较低表明了这一点。然而,MTF-GHPA患者的激素缓解率较低(30.8%),术后并发症较多(31.0%),这意味着STF-GHPA(激素缓解率:71.6%;术后并发症:13.4%)的内分泌结局优于MTF-GHPA患者。在MTF-GHPA内的PIT-1+SF-1+和PIT-1+TPIT+亚型之间,在肿瘤大小、内分泌结局和术后并发症方面也观察到显著差异。影响GHPA激素缓解的风险因素包括术前GH水平、原发性/复发性、切除范围和转录因子表达。

结论

多种转录因子的共表达是与GHPA患者临床行为和内分泌结局相关的重要因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验